tbuckley/cabot-search huggingface dataset:
Association Between Adult Acne and Dietary Behaviors
Authors: Laetitia Penso, Mathilde Touvier, Mélanie Deschasaux, Fabien Szabo de edelenyi, Serge Hercberg, Khaled Ezzedine, Emilie Sbidian
Journal: JAMA Dermatology (2020)

<h3>Importance</h3> Acne is a chronic, multifactorial inflammatory disease. The association between consumption of dairy products and fatty and sugary foods and occurrence and progression of acne remains unclear. <h3>Objective</h3> To assess the association between dietary behavior and current acne in adults. <h3>Design, Setting, and Participants</h3> A cross-sectional study was performed as part of the NutriNet-Santé study, which is an ongoing observational, web-based cohort study that was launched in France in May 2009. The present study was conducted from November 14, 2018, to July 8, 2019. A total of 24 452 participants completed an online self-questionnaire to categorize their acne status: never acne, past acne, or current acne. Associations between dietary behavior (food intake, nutrient intake, and the dietary pattern derived from a principal component analysis) and current or past acne were studied in multinomial logistic regression models adjusted for potential confounding variables (age, sex, physical activity, smoking status, educational level, daily energy intake, number of dietary records completed, and depressive symptoms). <h3>Results</h3> The 24 452 participants (mean [SD] age, 57 [14] years; 18 327 women [75%]) completed at least 3 dietary records. Of these, 11 324 individuals (46%) reported past or current acne. After adjustment, there was a significant association between current acne and the consumption of fatty and sugary products (adjusted odds ratio [aOR], 1.54; 95% CI, 1.09-2.16), sugary beverages (aOR, 1.18; 95% CI, 1.01-1.38), and milk (aOR, 1.12; 95% CI, 1.00-1.25). An energy-dense dietary pattern (high consumption of fatty and sugary products) was associated with current acne (aOR, 1.13; 95% CI, 1.05-1.18). <h3>Conclusions and Relevance</h3> In this study, consumption of milk, sugary beverages, and fatty and sugary products appeared to be associated with current acne in adults. Further large-scale studies are warranted to investigate more closely the associations between diet and adult acne.
New methodologies in ageing research
Authors: Brenna Osborne, Daniela Bakula, Michael Ben Ezra, Charlotte Dresen, Esben Hartmann, Stella M. Kristensen, Garik V. Mkrtchyan, Malte H. Nielsen, Michael A. Petr, Morten Scheibye-Knudsen
Journal: Ageing Research Reviews (2020)

Ageing is arguably the most complex phenotype that occurs in humans. To understand and treat ageing as well as associated diseases, highly specialised technologies are emerging that reveal critical insight into the underlying mechanisms and provide new hope for previously untreated diseases. Herein, we describe the latest developments in cutting edge technologies applied across the field of ageing research. We cover emerging model organisms, high-throughput methodologies and machine-driven approaches. In all, this review will give you a glimpse of what will be pushing the field onwards and upwards.
How to Rapidly Determine First-in-Children Dosing for COVID-19 Therapeutics
Authors: Kevin M. Watt
Journal: JAMA Pediatrics (2020)

Anil R. Maharaj, PhD; Huali Wu, PhD; Christoph P. Hornik, MD, PhD, MPH; Stephen J. Balevic, MD; Chi D. Hornik, PharmD; P. Brian Smith, MD; Daniel Gonzalez, PharmD, PhD; Kanecia O. Zimmerman, MD; Daniel K. Benjamin Jr, MD, PhD, MPH; Michael Cohen-Wolkowiez, MD, PhD; Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee
The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32
Authors: Isabel Pimentel, Bingshu E Chen, Ana Elisa Lohmann, Marguerite Ennis, Jennifer Ligibel, Lois Shepherd, Dawn L Hershman, Timothy Whelan, Vuk Stambolic, Ingrid Mayer, Timothy Hobday, Julie Lemieux, Alastair Thompson, Priya Rastogi, Karen Gelmon, Daniel Rea, Manuela Rabaglio, Susan Ellard, Mihaela Mates, Philippe Bedard, Lacey Pitre, Theodore Vandenberg, Ryan J O Dowling, Wendy Parulekar, Pamela J Goodwin
Journal: JNCI Journal of the National Cancer Institute (2020)

Metformin has been associated with lower breast cancer (BC) risk and improved outcomes in observational studies. Multiple biologic mechanisms have been proposed, including a recent report of altered sex hormones. We evaluated the effect of metformin on sex hormones in MA.32, a phase III trial of nondiabetic BC subjects who were randomly assigned to metformin or placebo.We studied the subgroup of postmenopausal hormone receptor-negative BC subjects not receiving endocrine treatment who provided fasting blood at baseline and at 6 months after being randomly assigned. Sex hormone-binding globulin, bioavailable testosterone, and estradiol levels were assayed using electrochemiluminescence immunoassay. Change from baseline to 6 months between study arms was compared using Wilcoxon sum rank tests and regression models.312 women were eligible (141 metformin vs 171 placebo); the majority of subjects in each arm had T1/2, N0, HER2-negative BC and had received (neo)adjuvant chemotherapy. Mean age was 58.1 (SD=6.9) vs 57.5 (SD=7.9) years, mean body mass index (BMI) was 27.3 (SD=5.5) vs 28.9 (SD=6.4) kg/m2 for metformin vs placebo, respectively. Median estradiol decreased between baseline and 6 months on metformin vs placebo (-5.7 vs 0 pmol/L; P < .001) in univariable analysis and after controlling for baseline BMI and BMI change (P < .001). There was no change in sex hormone-binding globulin or bioavailable testosterone.Metformin lowered estradiol levels, independent of BMI. This observation suggests a new metformin effect that has potential relevance to estrogen sensitive cancers.
Suggestions from Cremona, Italy: 2 months into the pandemic at the frontline of COVID-19 in Europe
Authors: A. Pan, M. Giorgi-Pierfranceschi, G. Bosio, L. Cammelli, R. Canino, A. Coluccello, A. Cuzzoli, A. Machiavelli, L. Romanini, A. Zoncada, S. Testa
Journal: Clinical Microbiology and Infection (2020)
FRI0447 FIRST COMPREHENSIVE LONG-TERM ASSESSMENT OF MUSCULOSKELETAL CONSEQUENCES AMONG EBOLA SURVIVORS
Authors: Y. M. Pers, A. Dubois, T. A. Barry, M. D. Sall, L. March, M. S. Sow, A. K. Keita, B. Taverne, J. F. Etard, A. Toure, M. Barry, E. Delaporte
Journal: Annals of the Rheumatic Diseases (2020)

Background: The tremendous size of the 2013-2016 West African outbreak of Ebola virus disease (EVD) resulted in a sizeable population of survivors, many reporting short-term sequelae such as arthralgia and myalgia. Objectives: We aimed to report a detailed and long-term description of patients’ musculoskeletal (MS) symptoms. Methods: We performed a cross-sectional study following systematic rheumatological screening of patients included in the Postebogui cohort (Conakry district). We used regression models to establish the magnitude of EVD as a risk factor for developing chronic MS pain by comparison with a control cohort and to establish risk factors for developing MS pain among survivors. Results: The study included 313 patients (55.6% female), with a median age of 28.2 years (IQR 21-37), and a median time from ETC discharge to rheumatological visit of 26.2 months (IQR 23-30). Chronic MS pain was reported in 216 (69%) patients, and was predominantly mechanical (48%). Enthesis and painful peripheral joints were largely involved (91%) with symmetrical distribution. Previous Ebola infection was a major risk factor for chronic MS pain (aOR, 6.662 [95% CI, 4.522–9.921]). Among survivors, increasing age (OR 1.14, 95% CI 1.08-1.22) and female gender (OR 3.58, 95% CI 1.22-11.80) were both associated with persistent MS pain, while myalgia experienced during the acute phase of EVD appeared protective (OR 0.14, 95% CI 0.04-0.42). Conclusion: Our study provides the most accurate long-term description of MS disorders among Ebola survivors. Joint and muscle pain sequelae are frequent and require specialized care. Disclosure of Interests: None declared
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation
Authors: Elisa Diral, Silvia Mori, Laura Antolini, Elisabetta Abruzzese, Philipp Le Coutre, Bruno Martino, Ester Pungolino, Chiara Elena, Micaela Bergamaschi, Sarit Assouline, Eros Di Bona, Antonella Gozzini, Marcio Andrade-Campos, Fabio Stagno, Alessandra Iurlo, Alessandra Pirola, Diletta Fontana, Jessica Petiti, Maria Luisa Bonanomi, Patrizia Crivori, Rocco Piazza, Carmen Fava, Carlo Gambacorti-Passerini
Journal: Blood (2020)
Abstract 10683: Nationwide Multicenter Study for Fontan Associated Liver Disease in Japan
Authors: Masaki Nii, Ryo Inuzuka, Yutaka Matsuyama, Satoshi Yasukouchi, Kei Inai, Isao Shiraishi, Atsuhito Takeda, Kouichiro Niwa, Shinichi Ootsuki, Teiji Akagi, Shigetoyo Kogaki, Atsushi Yao, Tadahiro Yoshikawa, HIroshi Ono, Keiichi Hirono, Takayuki Yamagishi, Yoshihide Mitani, Hideaki Senzaki, Toshio Nakanishi
Journal: Circulation (2018)

Introduction: Fontan associated liver disease (FALD) is increasingly recognized as a common complication in patients late after Fontan operation (FO). Increased central venous pressure and chronic ...
Reply to Wilson: Improving Lung Cancer Screening Uptake
Authors: Samantha L. Quaife, Mamta Ruparel, Jennifer L. Dickson, Rebecca J. Beeken, Andy McEwen, David R. Baldwin, Angshu Bhowmik, Neal Navani, Karen Sennett, Stephen W. Duffy, Jo Waller, Samuel M. Janes
Journal: American Journal of Respiratory and Critical Care Medicine (2020)
Upright Cheyne-Stokes Respiration in Patients With Heart Failure
Authors: Alberto Giannoni, Francesco Gentile, Paolo Sciarrone, Chiara Borrelli, Guido Pasero, Gianluca Mirizzi, Giuseppe Vergaro, Roberta Poletti, Massimo F. Piepoli, Michele Emdin, Claudio Passino
Journal: Journal of the American College of Cardiology (2020)
Breastfeeding Risk from Detectable Severe Acute Respiratory Syndrome Coronavirus 2 in Breastmilk
Authors: Chengliang Zhu, Weiyong Liu, Hanwen Su, Sitong Li, Muhammad Adnan Shereen, Zhihua Lv, Zhili Niu, Dong Li, Fang Liu, Zhen Luo, Yuchen Xia
Journal: Journal of Infection (2020)
Abstract PR05: A metabolomics discovery profiling approach identifies an E2F1-associated purine synthesis pathway as a major component of the MET-DNA damage response network
Authors: Michaela Poliaková, Matúš Medo, Jonas Koch, SiAna Coggins, Baek Kim, Daniel M. Aebersold, Nicola Zamboni, Michaela Medová, Yitzhak Zimmer
Journal: Cancer Research (2020)

Abstract Various lines of investigation support a signaling interphase shared by various receptor tyrosine kinases and the DNA damage response. However, the underlying driving network nodes and their contribution to the maintenance of DNA integrity remain unknown. We used discovery metabolomics combined with transcriptomics to identify changes in global metabolic pathways that are relevant to DNA repair following MET inhibition (METi). METi was associated with formation of γH2AX foci together with significant alterations in major metabolic circuits. Remarkably, 5′-phosphoribosyl-N-formylglycinamide (FGAR), a de novo purine synthesis pathway metabolite, was decreased in MET-dependent cancer models and a METi-related depletion of dNTPs was observed. Likewise, METi instigated the downregulation of critical purine synthesis enzymes including phosphoribosylglycinamide formyltransferase (GART), which is responsible for FGAR synthesis. Genes encoding these enzymes are regulated through the E2F1 transcription factor, whose levels decreased upon METi in MET-driven cells. To validate those findings, a transient E2F1 overexpression was sufficient to prevent MET targeting-dependent dNTPs depletion and the concomitant METi-associated DNA damage in MET-driven tumor cells. These novel observations support the notion that METi-mediated sensitization to DNA-damaging agents commonly used in cancer therapeutics is largely linked to the depletion of critical metabolites used in DNA repair due to downregulation of key metabolic enzymes whose expression is regulated through MET signaling. This abstract is also being presented as Poster A51. Citation Format: Michaela Poliaková, Matúš Medo, Jonas Koch, SiAna Coggins, Baek Kim, Daniel M. Aebersold, Nicola Zamboni, Michaela Medová, Yitzhak Zimmer. A metabolomics discovery profiling approach identifies an E2F1-associated purine synthesis pathway as a major component of the MET-DNA damage response network [abstract]. In: Proceedings of the AACR Special Conference on the Evolving Landscape of Cancer Modeling; 2020 Mar 2-5; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2020;80(11 Suppl):Abstract nr PR05.
Regulation of natural killer cell activity by glucocorticoids, serotonin, dopamine, and epinephrine
Authors: Silvia Capellino, Maren Claus, Carsten Watzl
Journal: Cellular and Molecular Immunology (2020)

The immune system and the nervous system are highly complex organs composed of various different cells that must interact with each other for proper function of the system. This communication can be mediated by soluble factors. The factors released by the nervous system (neurotransmitters) differ from those released by the immune system (cytokines). Nevertheless, the nervous and immune systems can influence each other's activity because immune cells express neurotransmitter receptors, and neurons express cytokine receptors. Moreover, immune cells can synthesize and release neurotransmitters themselves, thus using neurotransmitter-mediated pathways via autocrine and paracrine mechanisms. Natural killer (NK) cells are innate lymphocytes that are important for early and effective immune reactions against infections and cancer. Many studies have shown the strong influence of stress and the nervous system on NK cell activity. This phenomenon may be one reason why chronic stress leads to a higher incidence of infections and cancer. Here, we review the effects of neuroendocrine factors on the different activities of NK cells. Understanding the effects of neuroendocrine factors on NK cell activities during physiological and pathophysiological conditions may result in novel therapeutic strategies to enhance NK cell functions against tumors.
RV‐C infections result in greater clinical symptoms and epithelial responses compared to RV‐A infections in patients with CRS
Authors: Amanda L. Willis, Joshua B. Calton, Jaeden Calton, Alexander S. Kim, Ray Lee, Elmira Torabzadeh, Dean D. Billheimer, Christopher H. Le, Fernando D. Martinez, Eugene H. Chang
Journal: Allergy (2020)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.
Authors: Thierry Andre, Kai-Keen Shiu, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J. A. Punt, Denis Michel Smith, Rocio Garcia-Carbonero, Manuel Benavides, Peter Gibbs, Christelle De La Fouchardiere, Fernando Rivera, Elena Elez, Johanna C. Bendell, Dung T. Le, Takayuki Yoshino, Ping Yang, Mohammed Zulfiqar Husain Farooqui, Patricia Marinello, Luis A. Diaz
Journal: Journal of Clinical Oncology (2020)

LBA4 Background: KEYNOTE-177 (NCT02563002) is a phase 3, randomized open-label study evaluating the efficacy and safety of pembrolizumab (pembro) versus standard of care chemotherapy ± bevacizumab or cetuximab (chemo) as first-line therapy for patients (pts) with microsatellite-instability high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). We present results of the final PFS analysis. Methods: A total of 307 pts with MSI-H/dMMR mCRC as determined locally and ECOG PS 0 or 1 were randomly assigned 1:1 to first-line pembro 200 mg Q3W for up to 2 years or investigator’s choice of mFOLFOX6 or FOLFIRI Q2W ± bevacizumab or cetuximab (chemo chosen prior to randomization). Treatment continued until PD, unacceptable toxicity, pt/investigator decision to withdraw, or completion of 35 cycles (pembro only). Patients receiving chemo could crossover to pembro for up to 35 cycles after confirmed PD. Primary end points were PFS (RECIST v1.1, central review) and OS. Key secondary end points included ORR (RECIST v1.1, central review), and safety. The data cutoff date for this interim analysis was Feb 19, 2020. The study will continue without changes to evaluate OS. Results: At data cutoff, 153 pts were randomized to pembro and 154 to chemo. Median (range) study follow-up was 28.4 mo (0.2-48.3) with pembro vs 27.2 mo (0.8-46.6) with chemo. Pembro was superior to chemo for PFS (median 16.5 mo vs 8.2 mo; HR 0.60; 95% CI, 0.45-0.80; P=0.0002). The 12- and 24-mo PFS rates were 55.3% and 48.3% with pembro vs 37.3% and 18.6% with chemo. Confirmed ORR was 43.8% vs 33.1%; median (range) duration of response was not reached (2.3+ to 41.4+) with pembro vs 10.6 mo (2.8 to 37.5+) with chemo. Grade 3-5 treatment related adverse event (AE) rates were 22% vs 66% for pembro vs chemo. One pt in the chemo arm died due to a treatment-related AE. Conclusions: Pembro provided a clinically meaningful and statistically significant improvement in PFS versus chemo as first-line therapy for pts with MSI-H/dMMR mCRC, with fewer treatment-related AEs observed and should be the new standard of care for these pts. Clinical trial information: NCT02563002 .
Abstract 14063: Human CD271+ Adipose-Derived Stem Cells Possess Angiogenic Capacity Through Mediating M2-Dominant Macrophage Polarization in Cell Therapy
Authors: Kosei Yamaguchi, Oto Inoue, Yusuke Takeda, Chiaki Goten, Shinichiro Takashima, Soichiro Usui, Kenji Sakata, Masa-aki Kawashiri, Masayuki Takamura
Journal: Circulation (2019)

Background: Cell therapy using adipose-derived stem cells (ADSCs) is an attractive treatment for cardiovascular diseases. Recently, ADSCs have been reported to mediate M2-dominant polarization (M2D...
Is self‐reported history of eczema and hay fever a valid measure of atopy in those who report current asthma?
Authors: Kathrine Pape, Vivi Schlünssen, Caroline Jane Lodge, Jennifer L. Perret, E. Haydn Walters, Dinh Bui, Bircan Erbas, Cecilie Svanes, Garun S. Hamilton, Paul S. Thomas, Karin S. Hougaard, Michael J. Abramson, Shyamali C. Dharmage, Adrian J. Lowe
Journal: Allergy (2020)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Brain Volume Changes Under Treatment With Antipsychotics—Reply
Authors: Aristotle N. Voineskos, Erin W. Dickie, Benoit H. Mulsant
Journal: JAMA Psychiatry (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
AB1333-HPR FIBROMYALGIA SYNDROME IN MEDICAL STUDENTS
Authors: İ. Akcin, M. Gur, R. Piskin Sagir, B. Oz, A. Karatas, S. S. Koca
Journal: Annals of the Rheumatic Diseases (2020)

Background: At the university, students begin to be responsible for their own life decisions and lifestyles. First year students are required to adapt especially to a new learning environment and to cope with the academic and social demands of vocational education. High academic expectations are stressful and can pose a risk to students mental and physical health. Anxiety and depression are among the most common psychiatric problems among students. Objectives: The aim of this study is to evaluate the prevalence of fibromyalgia syndrome (FMS) in medical students and to compare students from engineering faculty. Methods: 392 (284 faculty of medicine, 108 faculty of engineering) students selected from Firat University Faculty of Medicine and Engineering were included in the study. Hospital Anxiety and Depression Scale (HADS) forms were filled in for all participants. Anxiety and depression among students of medical and engineering were examined. Moreover, 2016 ACR FMS classification criteria was used to select the student who have FMS. Results: In our sample, 185 (47.1%) and 207 (52.9%) of participants were male and female, respectively. HADS anxiety and HADS depression scores were significantly higher in engineering students than in medical students (mean HADS anxiety and depression scores were 9.07; 10.29, p= 0.007 and 7.61; 8.52, p= 0.039, respectively). While a significant difference was found among medical and engineering students in terms of HADS anxiety and depression scores in men (p&lt;0.001 and p= 0.006), no significant difference was found in women (p= 0.676 and p= 0.278). On the other hand, 46 (16.1%) of medical students and 13 (11.7%) of students from engineering faculty have FMS (p=0.170). Conclusion: FMS prevalences are similar in the medical students and students from engineering faculty. However, anxiety and depression are more common among male engineering students than medical students. This may be related to future employment anxiety among students from engineering faculty. References: [1]Cheung T, et al. Depression, Anxiety and Symptoms of Stress among Baccalaureate Nursing Students in Hong Kong: A Cross-Sectional Study. Int J Environ Res Public Health. 2016 Aug 3;13(8). Disclosure of Interests: None declared
Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta‐Analyses Supporting American Association for the Study of Liver Diseases Guidelines
Authors: John M. Vierling, Nanda Kerkar, Albert J. Czaja, Cara L. Mack, David Adams, David N. Assis, Michael P. Manns, Marlyn J. Mayo, Tarek Nayfeh, Abdul Mounaem M. Majzoub, Muayad A. Alzuabi, Jingyi Ding, Samir Haffar, M. Hassan Murad, Mouaz Alsawas
Journal: Hepatology (2020)

Vierling, John M.; Kerkar, Nanda; Czaja, Albert J.; Mack, Cara L.; Adams, David; Assis, David N.; Manns, Michael P.; Mayo, Marlyn J.; Nayfeh, Tarek; Majzoub, Abdul Mounaem M.; Alzuabi, Muayad A.; Ding, Jingyi; Haffar, Samir; Murad, M. Hassan; Alsawas, Mouaz Author Information